Showing 2581-2590 of 3872 results for "".
- ASPS: More than $16 Billion Spent on Cosmetic Plastic Surgery in 2016https://modernaesthetics.com/news/asps-more-than-16-billion-spent-on-cosmetic-plastic-surgery-in-2016/2472246/Americans spent more than ever before – $16 billion – on cosmetic plastic surgery and minimally-invasive procedures in 2016, according to a new report from the American Society of Plastic Surgeons (ASPS). The new report also breaks
- Restylane® Refyne and Restylane® Defyne Show Lasting Natural Benefit in Phase 4 Studieshttps://modernaesthetics.com/news/restylane-refyne-and-restylane-defyne-show-lasting-natural-benefit-in-phase-4-studies/2472251/Two Phase 4 clinical studies of Restylane® Refyne and Restylane® Defyne show that the natural-looking results last. Specifically, the Natural Expression study found that naturalness in facial expressions was at least main
- Breaking Business News: Apax Partners to Acquire Syneronhttps://modernaesthetics.com/news/breaking-business-news-apax-partner-to-acquire-syneron/2472253/An affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Syneron Candela for $11.00 per share in cash in a transaction valued at approximately $397 million. The per share acquisition price represe
- Survey: Many Bothered By Double Chins, Take Steps To Cover Uphttps://modernaesthetics.com/news/survey-many-bothered-by-double-chins-take-steps-to-cover-up/2472259/Close to 50 percent of individuals are bothered by the appearance of the area under their chin, and many alter their behavior as a result, according to a new survey commissioned by Allergan plc.<
- Zeltiq Showcases CoolAdvantage Petite Applicator at AAD Annual Meetinghttps://modernaesthetics.com/news/zeltiq-showcases-cooladvantage-petite-applicator-at-aad-annual-meeting/2472261/ZELTIQ® Aesthetics is showcasing the CoolAdvantage Petite™ applicator at the American Academy of Dermatology Annual Meeting (AAD) in Orlando. The CoolAdvantage technology is the only non-invasive fat removal technology cleared by the
- Galderma, Colorescience to Collaborate on Innovative Skincarehttps://modernaesthetics.com/news/galderma-colorescience-to-collaborate-on-innovative-skincare/2472266/Galderma will collaborate with Colorescience to expand skincare solutions to individuals who seek innovative daily skincare products that can be used in conjunction with traditional facial injectable aesthetic treatments, the companies have announced. Galderma and
- ASPS 2016 Stats: Cosmetic Surgery On The Risehttps://modernaesthetics.com/news/asps-2016-stats-cosmetic-surgery-on-the-rise/2472267/Fat is still phat – at least in some places like the breasts, butt and face, according to the annual statistics from the American Society of Plastic Surgeons (ASPS). Specifically, minimally invasive cosmetic fat injections incre
- Deadline Extended for Medical Spa State of the Industry Statistical Studyhttps://modernaesthetics.com/news/deadline-extended-for-medical-spa-state-of-the-industry-statistical-study/2472272/The American Med Spa Association (AmSpa) has extended the deadline for the 2017 Medical Spa St
- Aesthetics Wire Exclusive: AAFPRS Survey Shows Combination Facial Plastic Surgery Treatment Requests Are Soaringhttps://modernaesthetics.com/news/aesthetics-wire-exclusivecombination-facial-plastic-surgery-treatment-requests-soaring/2472289/Combination therapies reign supreme, according to the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) 2016 statistics. In 2016, 66 percent of facial plastic surgeons reported performing combined non-surgical procedures in the same
- Update: Revance Starts Phase III Studies on RT002 for Frown Lineshttps://modernaesthetics.com/news/revance-starts-phase-iii-studies-on-rt002-for-frown-lines/2472297/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials